Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Iranian Consensus on Use of Vitamin D in Patients With Multiple Sclerosis Publisher Pubmed



Jahromi SR1, 2 ; Sahraian MA1, 3 ; Togha M3, 4 ; Sedighi B5 ; Shayegannejad V6 ; Nickseresht A7 ; Nafissi S8 ; Mohebbi N9 ; Majdinasab N10 ; Foroughipour M11 ; Etemadifar M12 ; Moghadam NB13 ; Ayramlou H14 ; Ashtari F6 Show All Authors
Authors
  1. Jahromi SR1, 2
  2. Sahraian MA1, 3
  3. Togha M3, 4
  4. Sedighi B5
  5. Shayegannejad V6
  6. Nickseresht A7
  7. Nafissi S8
  8. Mohebbi N9
  9. Majdinasab N10
  10. Foroughipour M11
  11. Etemadifar M12
  12. Moghadam NB13
  13. Ayramlou H14
  14. Ashtari F6
  15. Alaie S1

Source: BMC Neurology Published:2016


Abstract

Background: Accumulating evidences from experimental, epidemiologic and clinical studies support the potential linkage between poor vitamin D status and the risk of developing Multiple Sclerosis (MS), as well as, an adverse disease course. However, the results of the trials on the clinical outcomes of vitamin D supplementation in MS patients are less consistent which brought many discrepancies in routine practice. In this article we presented a summary of a symposium on vitamin D and MS. In this symposium we aim to review the current data about the relationship between vitamin D and MS, and suggest management guides for practicing neurologists. Discussion: Generally, supplementation seems to be reasonable for all MS and clinically isolated syndrome (Rinaldi et al., Toxins 7:129-37, 2015) patients with serum 25(OH)D level below 40ng/ml. In patients with vitamin D insufficiency or deficiency, a large replacing dose (e.g. 50,000IU capsules of D per week for 8-12 week) is recommended. Panel also suggested: the checking of the serum vitamin D, and calcium level, as well as, patients' compliance after the initial phase; a maintenance treatment of 1500-2000IU daily or equivalent intermittent (weekly, biweekly or monthly) Dose, considering the patient's compliance; routine check of serum vitamin D level at least two times a year especially at the beginning of spring and autumn; Serum vitamin D evaluation for first degree relatives of MS patients at high risk age and supplementation in case of insufficiency (25(OH)D less than 40 ng/ml); correction of vitamin D deficiency and insufficiency before pregnancy, as well as, a daily dose of 1500-2000IU or equivalent biweekly intake in 2nd and 3rd trimesters; stopping supplementation if 25(OH)D serum level exceeds 100ng/ml. Summary: Although the results of high power studies are not available, correcting vitamin D status seems plausible in all MS and CIS patients. Maintaining the serum 25(OH)D level between 40 and 100 ng/ml is not known to exert adverse effect. More ever, it might be associated with lower disease activity. © 2016 Jahromi et al.
Other Related Docs
12. Is the Association Between Vitamin D and Metabolic Syndrome Independent of Other Micronutrients?, International Journal for Vitamin and Nutrition Research (2015)